How I approach iron deficiency with and without anemia.
Jacquelyn M PowersSarah H O'BrienPublished in: Pediatric blood & cancer (2018)
Iron deficiency anemia remains a common referral to the pediatric hematology-oncology subspecialist. Improved understanding of iron homeostasis, including the effects of the regulatory hormone hepcidin, recent adult and pediatric clinical trial data, as well as the availability of safer formulations of intravenous iron, have resulted in additional considerations when making treatment recommendations in such patients. Young children and adolescent females remain the most commonly affected groups, but children with complex medical or chronic inflammatory conditions including comorbid gastrointestinal disorders also require special consideration.
Keyphrases
- iron deficiency
- clinical trial
- young adults
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- childhood cancer
- mental health
- prognostic factors
- palliative care
- oxidative stress
- transcription factor
- high dose
- peritoneal dialysis
- electronic health record
- randomized controlled trial
- patient reported outcomes
- low dose
- combination therapy
- data analysis